

Toralizumab

Cat. No.:	HY-P99325
CAS No.:	252662-47-8
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, an immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research ^{[1][2]} .
IC ₅₀ & Target	CD40L

REFERENCES

- [1]. Camilo E Fadul, et al. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. *Neurol Neuroimmunol Neuroinflamm*. 2021 Oct 15;8(6):e1096.
- [2]. Kenneth C Kalunian, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2002 Dec;46(12):3251-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA